As a leader in microbiome biotechnology, our team capitalizes on an exclusive Asian microbiome biobank to tackle a myriad of diseases including COVID-19, colorectal cancer, obesity, eczema, and autism.
The gut microbiota interact with our human cells to regulate many physiological processes, such as metabolism and immune response, dysbiosis may lead to Weakened Immunity. By G-NiiB testing and technologies, we aim at modulating human gut microbiome to boost our Immunity.
